Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine as a Performance-enhancing Drug in HFpEF
2018-002170-52Phase 2Completed
- Sponsor
- VU University Medical Center (VUmc)
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trimetazidine in heart failure with preserved ejection fraction (HFpEF), sponsored by VU University Medical Center (VUmc). Primary endpoint: Exercise pulmonary capillary wedge pressure. Started Jan 2019; status: completed.
02
Drugs
trimetazidine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2018-002170-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002170-52.